Kratom Addiction: Signs, Withdrawal & Treatment

Kratom addiction develops when repeated use of Mitragyna speciosa leaf products produces compulsive use, tolerance, and withdrawal that a person cannot stop on their own. The plant’s alkaloids act on the same brain receptors as opioids, which is why dependence forms.

Kratom is sold as a natural supplement in gas stations and smoke shops across much of the country. That framing leads many people to assume it carries no dependence risk.

In Indiana, kratom is illegal outright, which changes both how dependence forms and how people obtain it.

Understanding the pharmacology explains why stopping produces genuine withdrawal rather than simple discomfort.

Key Takeaways

• The National Institute on Drug Abuse states that mitragynine and 7-hydroxymitragynine activate mu-opioid receptors, though the resulting effects only partially compare to those of opioids such as heroin or oxycodone.
• NIDA reports that kratom leaf and mitragynine have not been found to cause respiratory depression. 7-hydroxymitragynine has, and that depression can be reversed with naloxone.
• Indiana classifies mitragynine and 7-hydroxymitragynine under its synthetic drug statute at Indiana Code 35-31.5-2-321, making possession and sale criminal offenses statewide since Senate Bill 305 passed in 2014.
• The Food and Drug Administration has approved no drug product containing kratom or its alkaloids, and clinicians manage withdrawal with symptom-targeted medications and, in opioid-overlap cases, buprenorphine.
• Symptoms typically begin 6 to 12 hours after the last dose and peak between days 2 and 4. Physical symptoms resolve within about a week, while psychological symptoms persist for weeks.

What Is Kratom Addiction?

Kratom addiction is a substance use disorder in which a person continues using Mitragyna speciosa products despite escalating harm, meeting the same behavioral criteria that define dependence on any other psychoactive substance. The distinction between physiological adaptation and disorder matters clinically.

Kratom does not have its own diagnostic category in the DSM-5-TR. Clinicians code problematic use as other (or unknown) substance use disorder, applying the standard eleven criteria.

That coding gap explains why kratom cases are undercounted in national treatment data. It also makes the distinction between dependence and addiction especially important, since many users began kratom to manage pain or fatigue.

How Kratom Affects the Brain

Kratom’s psychoactive effects arise from more than forty alkaloids, of which two account for nearly all clinically relevant activity. Their receptor behavior explains both the appeal and the dependence.

Mechanisms established in pharmacology research:

• Mitragynine as a partial mu-opioid agonist: Mitragynine binds the mu-opioid receptor with partial agonist activity, producing analgesia and mild euphoria at higher doses without the full receptor activation that potent opioids generate.
• 7-hydroxymitragynine potency: This minor alkaloid and active metabolite binds mu-opioid receptors far more potently than mitragynine, which is why concentrated 7-OH products behave differently from traditional leaf powder.
• Biased agonism: Mitragynine preferentially engages G-protein signaling over the beta-arrestin-2 pathway, and researchers have proposed this biased agonism as the reason leaf kratom produces less respiratory depression than conventional opioids.
• Adrenergic and serotonergic activity: At low doses, mitragynine acts on alpha-2 adrenergic and serotonergic systems, producing the stimulant effect users report before opioid-like sedation appears at higher doses.
• Mitragynine pseudoindoxyl: This rearrangement product of the parent alkaloid shows distinct receptor activity and appears in some extract products, contributing to unpredictable potency between batches.

Kratom Product Types and Potency Differences

Kratom product formulation determines dependence risk more than total quantity consumed, because concentration varies by orders of magnitude across product categories.

Product forms and their clinical profile:

• Raw leaf powder and capsules: These contain naturally occurring alkaloid ratios with only trace 7-hydroxymitragynine, and they produce the mildest dependence pattern.
• Standardized extracts: Extracts concentrate alkaloids several-fold, compressing the timeline to physiological dependence from months into weeks.
• Concentrated 7-OH tablets and shots: Products marketed for potency and colloquially called gas station heroin deliver high 7-hydroxymitragynine doses, and these carry the highest withdrawal severity and overdose risk.
• Kratom and kava tonics: Ready-to-drink botanical tonics sold in convenience stores, including products such as Feel Free, combine kratom alkaloids with other actives and have generated substantial dependence reports.
• Adulterated products: The Food and Drug Administration has issued repeated import alerts, and contamination with heavy metals, salmonella, and undisclosed synthetic opioids has been documented in commercial samples.

How Clinicians Measure Kratom Withdrawal Severity

Because kratom withdrawal resembles opioid withdrawal, clinicians assess it using validated opioid withdrawal instruments rather than kratom-specific tools.

Assessment instruments used in detox settings:

• Clinical Opiate Withdrawal Scale (COWS): This eleven-item clinician-administered scale scores pulse, sweating, restlessness, pupil size, bone aches, gastrointestinal upset, tremor, yawning, anxiety, and gooseflesh. Totals of 13 to 24 indicate moderate withdrawal and scores above 36 indicate severe withdrawal.
• Subjective Opiate Withdrawal Scale (SOWS): This self-report instrument captures the person’s own symptom intensity, which frequently exceeds observable signs during kratom withdrawal.
• Comprehensive metabolic panel and liver function testing: Baseline hepatic testing screens for the cholestatic liver injury associated with heavy kratom use.
• Urine toxicology with expanded panels: Standard opioid screens do not detect mitragynine, so specific testing is required to confirm kratom use and rule out concurrent opioid exposure.

What Causes Kratom Dependence

Kratom dependence results from receptor adaptation, individual metabolic variation, developmental risk factors, and the specific self-treatment patterns that draw people to kratom in the first place.

Neurobiological Causes

Repeated mu-opioid receptor activation produces the same adaptive changes that drive dependence on prescription and illicit opioids.

Adaptations documented in dependence research:

• Receptor downregulation: Sustained mitragynine exposure reduces mu-opioid receptor sensitivity, requiring escalating doses to achieve the original effect.
• Endogenous opioid suppression: Continuous external receptor activation suppresses natural endorphin and enkephalin production, so baseline comfort depends on continued dosing.
• Locus coeruleus hyperactivity: Opioid receptor activation inhibits noradrenergic firing in the locus coeruleus, and abrupt cessation releases that inhibition, generating the sweating, agitation, and gastrointestinal symptoms of withdrawal.
• Mesolimbic dopamine adaptation: Repeated exposure shifts the mesolimbic reward pathway toward cue-driven craving, which persists after physical symptoms resolve.
• Short half-life dosing pressure: Mitragynine’s relatively short duration pushes users toward frequent redosing, and multiple daily doses accelerate tolerance more than equivalent single doses would.

Genetic and Metabolic Factors

Individual variation in drug metabolism and inherited risk explains why some users develop dependence rapidly while others do not.

Hereditary and metabolic contributors:

• CYP2D6 polymorphism: Mitragynine is metabolized substantially by CYP2D6, and poor metabolizers accumulate higher plasma concentrations at identical doses, raising both effect and dependence risk.
• CYP3A4 interactions: Concurrent medications that inhibit CYP3A4 elevate mitragynine exposure, which produces unexpected sedation and respiratory risk.
• Substance use disorder heritability: Twin and adoption studies place heritability of substance use disorders between 40 and 60 percent, and that inherited vulnerability applies to kratom as to any other agonist.
• Prior opioid exposure: Individuals with a history of opioid use disorder develop kratom dependence faster because receptor systems remain sensitized from earlier exposure.

Developmental and Environmental Causes

Environmental access and developmental history shape who begins using kratom and who escalates.

Contextual drivers of kratom use:

• Retail availability and supplement framing: In states without bans, unrestricted retail sale alongside vitamins signals safety, and that perception delays help-seeking by months or years.
• Chronic pain and opioid prescribing restriction: Many users begin kratom after opioid prescriptions are tapered or discontinued, substituting an unregulated agonist for a monitored one.
• Adverse childhood experiences: Elevated ACE scores predict substance use disorder onset generally, and trauma-related pain and insomnia are common stated reasons for beginning kratom.
• Occupational demand: Shift workers and professionals use kratom for its low-dose stimulant effect to sustain long hours, a pattern that produces daily dosing quickly.
• Prohibition-driven acquisition patterns: Where kratom is banned, as it is throughout Indiana, users obtain product through online mail order or out-of-state purchase, which favors bulk buying and higher-concentration extracts.

Co-Occurring Conditions

Psychiatric conditions frequently precede kratom use, and each drives use through an identifiable mechanism.

Conditions commonly present in kratom dependence:

• Major depressive disorder: Low-dose kratom’s stimulant effect temporarily relieves anergia and low mood, which establishes daily use before dependence is recognized.
• Generalized anxiety disorder: The anxiolytic effect at moderate doses reinforces use, and rebound anxiety during withdrawal typically exceeds the original baseline.
• Post-traumatic stress disorder: Kratom’s sedative properties suppress hyperarousal and nightmares, so cessation unmasks the trauma symptoms it was suppressing.
• Opioid use disorder in remission: Many users adopt kratom explicitly to manage opioid cravings, which substitutes one mu-opioid agonist for another and requires integrated co-occurring treatment rather than kratom cessation alone.
• Attention-deficit hyperactivity disorder: Stimulant-range dosing improves subjective focus, producing a self-medication pattern that persists until tolerance eliminates the benefit.

Kratom Withdrawal Timeline

Kratom withdrawal follows a recognizable sequence that clinicians can anticipate and medicate, and severity scales with daily dose, product concentration, and duration of use.

1. Hours 6 to 12, onset: Restlessness, mild anxiety, faint body aches, watery eyes, and runny nose appear, and many people mistake this phase for the start of a cold.
2. Hours 12 to 24, escalation: Sweating increases, muscle and joint pain intensifies, nausea begins, and sleep becomes difficult, which is when most self-directed attempts fail.
3. Days 2 to 4, peak: Symptoms converge across systems with vomiting, diarrhea, abdominal cramping, alternating chills and sweating, tremor, severe insomnia, and intense craving, and this window carries the highest relapse risk.
4. Days 4 to 7, physical resolution: Fever resolves, gastrointestinal symptoms improve, and muscle pain becomes manageable, while depression and craving frequently persist or intensify.
5. Days 7 to 14, insomnia persistence: Sleep disruption is typically the last physical symptom to resolve and often continues well into the second week.
6. Weeks 2 to 6, post-acute withdrawal: Low mood, anhedonia, poor concentration, and intermittent cravings define the post-acute phase, and heavy long-term users and concentrated 7-OH users occupy the longer end of that range.

Concentrated 7-hydroxymitragynine products, co-use of opioids or benzodiazepines, and higher daily intake all extend this timeline, which is why withdrawal symptom management in a monitored setting produces higher completion rates than unsupervised cessation.

Signs and Symptoms of Kratom Addiction

Kratom addiction presents across a severity spectrum, and recognizing which tier applies determines whether outpatient tapering or medically supervised detox is appropriate.

Common Signs of Kratom Addiction

Early kratom addiction produces behavioral and physical changes that users frequently attribute to stress or poor sleep rather than to the substance.

Frequently reported early indicators:

• Escalating dose and frequency: The person increases grams per dose or doses per day to maintain the original effect, which signals established tolerance.
• Interdose withdrawal: Irritability, sweating, and restlessness emerge between doses, and the person redoses to feel normal rather than to feel elevated.
• Constipation: Persistent constipation is among the most consistent physical signs and reflects mu-opioid receptor activity in the gastrointestinal tract.
• Preoccupation with supply: The person stockpiles product, monitors quantity remaining, and experiences anxiety when supply runs low.
• Failed reduction attempts: Repeated unsuccessful efforts to cut back or stop meet a core DSM-5-TR criterion for substance use disorder.
• Weight loss and appetite suppression: Reduced appetite and unintended weight loss appear commonly in daily users.

Severe Symptoms and Medical Emergencies

Several kratom-related presentations require emergency medical evaluation rather than a scheduled treatment admission.

Emergency indicators requiring immediate medical care:

• Respiratory depression: Slow, shallow, or stopped breathing after concentrated 7-OH use is a medical emergency, and NIDA notes this depression can be reversed with naloxone.
• Seizure activity: Seizures have been reported with high-dose kratom and with polysubstance combinations, and any seizure requires emergency evaluation.
• Signs of liver injury: Yellowing of the skin or eyes, dark urine, right upper abdominal pain, and severe fatigue indicate possible cholestatic hepatotoxicity and require urgent testing.
• Cardiac symptoms: Chest pain, racing heart rate, or QT-interval-related symptoms warrant emergency assessment, particularly with concurrent stimulant use.
• Rhabdomyolysis: Severe muscle pain with dark urine after heavy use signals muscle breakdown that can produce kidney failure.
• Psychosis or severe confusion: Hallucinations, disorientation, or paranoia require psychiatric emergency evaluation.

Long-Term Health Risks

Sustained heavy kratom use produces documented organ and neuropsychiatric consequences that persist beyond withdrawal.

Documented long-term outcomes:

• Cholestatic liver injury: Case series have documented kratom-induced liver injury with a predominantly cholestatic pattern, typically appearing two to eight weeks after use begins or escalates.
• Persistent insomnia and mood disturbance: Sleep architecture disruption and depressive symptoms frequently outlast acute withdrawal by weeks to months.
• Weight loss and nutritional deficiency: Chronic appetite suppression produces measurable nutritional deficits in long-term daily users.
• Hyperpigmentation: Darkening of facial skin has been reported in long-term heavy users, particularly in traditional-use populations.
• Neonatal abstinence syndrome: Infants born to mothers using kratom during pregnancy have required treatment for withdrawal, which makes prenatal disclosure clinically essential.

Kratom vs Opioid Withdrawal: How They Differ

Kratom withdrawal shares its mechanism with opioid withdrawal but differs in intensity, duration, and medical risk, and those differences change treatment planning.

Criterion	Kratom Withdrawal	Short-Acting Opioid Withdrawal	Concentrated 7-OH Withdrawal
Onset after last dose	6 to 12 hours	8 to 12 hours	4 to 8 hours
Peak intensity	Days 2 to 4	Days 1 to 3	Days 1 to 3
Acute duration	5 to 7 days	4 to 7 days	7 to 10 days
Peak physical severity	Mild to moderate	Moderate to severe	Moderate to severe
Post-acute phase	2 to 6 weeks	2 to 4 weeks	3 to 6 weeks
Respiratory depression risk	Low with leaf products	High	Present and naloxone-reversible
Detected on standard drug screen	No	Yes	No
Buprenorphine responsive	Yes, off-label	Yes, FDA-approved	Yes, off-label

The most consequential clinical difference is detection. Because mitragynine does not appear on standard opiate panels, clinicians who do not order expanded testing may misattribute a patient’s withdrawal to another cause or miss it entirely.

Kratom Legality in Indiana

Indiana prohibits kratom entirely, which distinguishes the state from the majority of the country and shapes how residents acquire and conceal the substance.

How Indiana Classifies Kratom

Indiana bans kratom’s active alkaloids through its synthetic drug statute rather than through a conventional controlled substance schedule.

Elements of Indiana’s kratom prohibition:

• Statutory basis: Indiana Code 35-31.5-2-321 lists mitragynine and 7-hydroxymitragynine as synthetic drugs, and Indiana treats synthetic drugs as Schedule I substances.
• Origin of the ban: Senate Bill 305, enacted in 2014, added the alkaloids to the synthetic drug list during a legislative response to synthetic cannabinoid products.
• Scope of prohibition: Possession, sale, manufacture, and importation are criminal offenses, and no exception exists for personal or therapeutic use.
• National context: The Congressional Research Service identifies Indiana among a small group of states banning kratom’s alkaloids under state analogues of the Controlled Substances Act, while kratom remains unscheduled at the federal level.
• Pending reform: Legislators have introduced bills to replace the ban with a regulatory framework, and none has been enacted, so Indiana’s kratom prohibition remains in force.

Clinical Implications of the Indiana Ban

Prohibition changes the clinical presentation of kratom dependence in Indiana residents in ways that affect assessment and treatment planning.

How the ban alters clinical presentation:

• Bulk acquisition patterns: Residents who obtain kratom through online mail order or out-of-state purchase buy in larger quantities and favor concentrated extracts, which produces more severe dependence than incremental retail purchasing.
• Higher concealment and later presentation: Legal exposure discourages disclosure to physicians and employers, so Indiana patients frequently present at a more advanced stage.
• Supply interruption withdrawal: Shipment delays and seizures produce involuntary abrupt cessation, and unplanned withdrawal episodes drive many first treatment contacts.
• Product uncertainty: Unregulated interstate sources increase exposure to adulterated and mislabeled product, which complicates toxicology interpretation at intake.
• Legal consequences as clinical context: Pending charges alter treatment motivation and require care coordination that voluntary-only presentations do not.

Treatment for Kratom Addiction

Kratom addiction responds to the same treatment architecture used for opioid use disorder, with medication selection adjusted for the absence of any kratom-specific approved agent.

First-Line Evidence-Based Therapies

Behavioral treatment addresses the craving and self-medication patterns that persist after physical withdrawal resolves.

Therapies with established efficacy:

• Cognitive behavioral therapy (CBT): CBT identifies the pain, fatigue, and mood triggers that preceded kratom dosing and builds specific alternative responses for each.
• Motivational interviewing: Clinicians use motivational interviewing to resolve the ambivalence created by kratom’s supplement framing, which many patients still hold at admission.
• Contingency management: Structured reinforcement for verified abstinence has strong behavioral evidence and adapts directly to kratom monitoring with expanded toxicology panels.
• Dialectical behavior therapy (DBT): DBT’s distress tolerance module targets the post-acute anhedonia and craving window where most relapse occurs.
• Eye movement desensitization and reprocessing (EMDR): EMDR addresses the trauma-related pain and hyperarousal that kratom was suppressing, sequenced after medical stabilization.

Pharmacological Treatment

No medication is approved specifically for kratom withdrawal, so clinicians combine symptom-targeted agents with opioid agonist therapy where receptor overlap justifies it.

Medications used in kratom detox and maintenance:

• Buprenorphine: Case series support buprenorphine for moderate to severe kratom withdrawal, used off-label, and clinicians must time initiation carefully to avoid precipitated withdrawal.
• Alpha-2 agonists: Clonidine and lofexidine suppress the noradrenergic surge from locus coeruleus disinhibition, reducing sweating, agitation, and cramping.
• Antiemetics: Ondansetron and promethazine control the nausea and vomiting that peak between days 2 and 4.
• Non-opioid analgesics: Non-steroidal anti-inflammatory drugs and acetaminophen manage the muscle and joint pain that defines the peak phase.
• Sleep and mood agents: Trazodone or hydroxyzine address the insomnia that persists longest, and SSRIs such as sertraline or escitalopram treat the depressive symptoms that emerge in the post-acute phase.
• Extended-release naltrexone: After full withdrawal completion, monthly injectable naltrexone blocks mu-opioid receptors and is used off-label for relapse prevention in kratom dependence.

Second-Line and Adjunct Treatments

Adjunct approaches address the pain, sleep, and social factors that commonly precipitated kratom use.

Supportive treatments that reduce relapse pressure:

• Non-opioid pain management: Physical therapy, targeted exercise, and non-opioid pharmacotherapy address the chronic pain that led many patients to kratom initially.
• Sleep restructuring: Cognitive behavioral therapy for insomnia treats the sleep disruption that outlasts acute withdrawal and predicts relapse.
• Group therapy: Peer groups reduce the isolation that kratom users report, particularly given the substance’s low recognition in general recovery communities.
• Twelve-step and peer support: Community recovery structures provide accountability after clinical treatment concludes.

Emerging and Investigational Treatments

Several developments in kratom research and adjacent addiction medicine may alter treatment within the next several years.

Investigational approaches and current status:

• Selective mu-opioid partial agonists: Research groups including Christopher McCurdy’s laboratory at the University of Florida are characterizing mitragynine analogues as potential analgesics with reduced dependence liability, and none has reached clinical approval.
• Transcranial magnetic stimulation (TMS): The FDA has cleared TMS for smoking cessation, and trials are examining prefrontal stimulation for opioid craving, which would extend to kratom by mechanism.
• Ketamine-assisted psychotherapy: Off-label ketamine paired with psychotherapy is under investigation for opioid use disorder, with esketamine already approved for treatment-resistant depression.
• N-acetylcysteine (NAC): This glutamate-modulating supplement is in trials as a craving-reduction adjunct across substance use disorders and remains investigational.

Kratom Detox and Rehabilitation at The Grove Estate

The Grove Estate treats kratom dependence through its medical detox and residential programs in Peru, Indiana. Placement follows American Society of Addiction Medicine criteria rather than the assumption that a botanical substance needs less clinical oversight.

Medically Supervised Kratom Detox

Kratom withdrawal peaks between days 2 and 4, and on-site medical supervision spans that window rather than ending after intake.

Detox components delivered on site:

• Physician-prescribed medication protocols: Medical detox at The Grove uses physician-prescribed medications with continuous monitoring throughout medically supervised withdrawal.
• Twenty-four-hour nursing oversight: Registered nurses monitor medical conditions continuously, which matters during the peak window when gastrointestinal symptoms and dehydration risk converge.
• Comprehensive medical evaluation: A medical provider performs a thorough physical examination and medication review, which identifies the hepatic and cardiac complications associated with heavy kratom use.
• Psychiatric evaluation: A psychiatric provider conducts a comprehensive psychiatric evaluation, establishing whether depression, anxiety, or trauma symptoms preceded kratom use or emerged during withdrawal.

Residential Rehabilitation After Detox

Post-acute kratom withdrawal extends two to six weeks, which places the highest-risk relapse window after physical detox concludes.

Residential programming that covers the post-acute window:

• Twenty-four-hour structured environment: Residential rehabilitation provides continuous clinical, nursing, and therapeutic structure through the anhedonia and craving phase.
• Individual and group counseling: Licensed clinicians deliver intensive, problem-specific individual sessions alongside group counseling addressing the emotional and behavioral drivers of chemical dependency.
• Wellness and physical rebuilding: Tailored physical wellness programming ranging from full workout protocols to relaxation techniques addresses the sleep disruption and deconditioning that follow chronic kratom use.
• Weekly psychiatric rounds: A psychiatric provider conducts weekly clinical rounds, allowing medication adjustment as post-acute symptoms evolve.
• Family programming: Family education and counseling addresses households where kratom use was concealed or misunderstood as supplement use.

Confidential Care for Working Professionals

Kratom’s low-dose stimulant effect makes it common among people sustaining long working hours, and Indiana’s prohibition adds legal exposure to professional risk.

Features relevant to professional clients:

• Discreet sanctuary setting: The Grove’s private estate setting in Peru, Indiana, separates clients from professional and social environments during treatment.
• Peer cohort of professionals: The program for working professionals places clients alongside peers who share comparable triggers, stressors, and confidentiality concerns.
• Non-coercive clinical philosophy: A trauma-informed, non-coercive approach suits clients who began kratom as self-treatment and respond poorly to framing that treats that decision as moral failure.
• Adult voluntary admission: The Grove serves voluntary adult clients aged 18 and older, and admission follows a clinical assessment rather than external mandate.

Dr. Steven Schneider, Medical Director at The Grove Estate, notes the assessment problem kratom creates.

“Patients tell us they took a supplement while describing textbook opioid withdrawal. Mitragynine does not appear on a standard panel, so without the specific question and the right test you treat the wrong thing.”

Frequently Asked Questions

What does kratom withdrawal feel like?

Most people describe it as a severe flu combined with intense restlessness and anxiety. Muscle aches, sweating, alternating chills, diarrhea, and near-total insomnia dominate days 2 through 4. Users consistently report the psychological component, particularly craving and low mood, as harder to tolerate than the physical symptoms.

How long does kratom stay in your system?

Mitragynine has an elimination half-life of roughly 24 hours in regular users, so detectable levels persist several days after the last dose. Standard urine drug screens do not detect mitragynine, and confirmation requires a specific expanded panel. This detection gap frequently delays accurate diagnosis in emergency settings.

Is kratom addiction as serious as opioid addiction?

Kratom dependence generally produces milder peak withdrawal than short-acting opioids, but often a longer post-acute phase. Concentrated 7-hydroxymitragynine products narrow that gap considerably and carry documented respiratory depression risk. Severity depends far more on product concentration and duration of use than on the substance category itself.

Can you taper off kratom at home?

Some people with low daily intake taper successfully with medical guidance, and tapering reduces peak severity while extending total duration. Home cessation carries high relapse risk during the day 2 to 4 peak, and anyone using concentrated extracts, high daily doses, or co-occurring opioids should taper under medical supervision.

Is kratom legal where I live?

Kratom is unscheduled at the federal level but banned in a small number of states, including Indiana, where mitragynine and 7-hydroxymitragynine fall under the synthetic drug statute. Most states regulate rather than prohibit it, often through Kratom Consumer Protection Acts. Legal status has changed repeatedly, so current state law should be verified directly.

Can kratom cause liver damage?

Yes. Published case series document kratom-induced liver injury with a predominantly cholestatic pattern, typically appearing two to eight weeks after use begins or escalates. Warning signs include yellowing skin or eyes, dark urine, and right upper abdominal pain. Baseline liver function testing is standard practice at detox admission.

Can you use kratom to get off opioids?

Many people attempt this, and kratom does reduce opioid withdrawal symptoms because it activates the same receptors. It substitutes one mu-opioid agonist for an unregulated one, and dependence transfers rather than resolves. Buprenorphine and methadone carry FDA approval for this purpose with dosing consistency that kratom products cannot provide.

Is kratom safe during pregnancy?

No. Infants born to mothers using kratom during pregnancy have required treatment for neonatal abstinence syndrome. Because kratom does not appear on standard drug screens, disclosure to the obstetric team is essential so that neonatal withdrawal can be anticipated rather than discovered after delivery.

References

1. Congressional Research Service. (2026). Temporary control of 7-hydroxymitragynine (7-OH) and related substances under the Controlled Substances Act (LSB11457). Library of Congress.
2. Congressional Research Service. (2024). Kratom regulation: Federal status and state approaches (LSB11082). Library of Congress.
3. American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). American Psychiatric Publishing.
4. Kruegel, A. C., & Grundmann, O. (2018). The medicinal chemistry and neuropharmacology of kratom: A preliminary discussion of a promising medicinal plant and analysis of its potential for abuse. Neuropharmacology, 134, 108–120.
5. Kamble, S. H., Berthold, E. C., King, T. I., Raju Kanumuri, S. R., Popa, R., Herting, J. R., León, F., Sharma, A., McMahon, L. R., Avery, B. A., & McCurdy, C. R. (2021). Pharmacokinetics of eleven kratom alkaloids following an oral dose of either traditional or commercial kratom products in rats. Journal of Natural Products, 84(4), 1104–1112.
6. Swogger, M. T., & Walsh, Z. (2018). Kratom use and mental health: A systematic review. Drug and Alcohol Dependence, 183, 134–140.
7. Eastlack, S. C., Cornett, E. M., & Kaye, A. D. (2020). Kratom: Pharmacology, clinical implications, and outlook: A comprehensive review. Pain and Therapy, 9(1), 55–69.
8. Substance Abuse and Mental Health Services Administration. (2024). Key substance use and mental health indicators in the United States: Results from the 2023 National Survey on Drug Use and Health. Center for Behavioral Health Statistics and Quality.
9. Wesson, D. R., & Ling, W. (2003). The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs, 35(2), 253–259.
10. Mee-Lee, D. (Ed.). (2013). The ASAM criteria: Treatment criteria for addictive, substance-related, and co-occurring conditions (3rd ed.). American Society of Addiction Medicine.
11. Indiana Code § 35-31.5-2-321 (2023). Synthetic drug definition.